2023
DOI: 10.1111/imr.13239
|View full text |Cite
|
Sign up to set email alerts
|

Gastrointestinal mucosal toxicities from immune checkpoint inhibitors: Current understanding and future directions

Abstract: SummaryImmune checkpoint inhibitor (ICI) therapy has revolutionized the field of oncology over the past decade, leading to durable remissions in some patients but also producing a wide spectrum of treatment‐limiting inflammatory toxicities that are referred to as immune‐related adverse events (irAEs). Although irAEs can involve any organ system in the body, they most commonly affect the barrier tissues, including the gastrointestinal tract with colitis and enterocolitis affecting a significant fraction of pati… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 91 publications
0
2
0
Order By: Relevance
“…The review by Michael Dougan provides a comprehensive review on the gastrointestinal (GI) toxicities caused by ICIs 32 . Although most of the GI irAEs are mild in nature, their high occurrence rate makes them the leading cause of severe toxicities associated with ICIs.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…The review by Michael Dougan provides a comprehensive review on the gastrointestinal (GI) toxicities caused by ICIs 32 . Although most of the GI irAEs are mild in nature, their high occurrence rate makes them the leading cause of severe toxicities associated with ICIs.…”
Section: Introductionmentioning
confidence: 99%
“…The review by Michael Dougan provides a comprehensive review on the gastrointestinal (GI) toxicities caused by ICIs. 32 Although most of the GI irAEs are mild in nature, their high occurrence rate makes them the leading cause of severe toxicities associated with ICIs. In his review, he provides an in-depth description of the clinical manifestations along with a thorough discussion of the immune mechanisms known to-date (e.g., gut CD8 + TRMs) associated with ICI-colitis, which is the most common GI toxicity associated with the use of ICIs.…”
mentioning
confidence: 99%